Evidence map›Paper›PMID 18505929›Full record

ArticleMolecular cancer research : MCR2008

Growth factor regulation of estrogen receptor coregulator PELP1 functions via Protein Kinase A pathway.

Jatin K Nagpal, Sujit Nair, Dimple Chakravarty, Rajib Rajhans, Saikumar Pothana, Darrell W Brann, Rajeshwar Rao Tekmal, Ratna K Vadlamudi

Open access · bronzeAbstract read
In one paragraph

Article in Molecular cancer research : MCR, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 34 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Minireview: Deciphering the Cellular Functions of PELP1.Molecular endocrinology (Baltimore, Md.) · 2015
    Review
  10. Article
  11. Article
  12. PELP1: a review of PELP1 interactions, signaling, and biology.Molecular and cellular endocrinology · 2014
    Review
  13. Significance of ER-Src axis in hormonal therapy resistance.Breast cancer research and treatment · 2011
    Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Extranuclear coactivator signaling confers insensitivity to tamoxifen.Clinical cancer research : an official journal of the American Association for Cancer Research · 2009
    Article
  19. PELP1--a novel estrogen receptor-interacting protein.Molecular and cellular endocrinology · 2008
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Jatin K NagpalDepartment of Obstetrics and Gynecology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, Mail Code 7836, San Antonio, TX 78229-3900, USA.
Sujit Nair
Dimple Chakravarty
Rajib Rajhans
Saikumar Pothana
Darrell W Brann
Rajeshwar Rao Tekmal
Ratna K Vadlamudi
Beijing Obstetrics and Gynecology Hospital · CNAugusta University · USThe University of Texas Health Science Center at San Antonio · US

Funding

Neuroprotective and Neurogenic Actions of E2 and SERMsR01NS050730 · NINDS · MEDICAL COLLEGE OF GEORGIA (MCG) · PI BRANN, DARRELL W, VADLAMUDI, RATNA K · 2005 to 2014
$3.2M
PELP1, a Novel Regulator of Estrogen ReceptorR01CA095681 · NCI · UNIVERSITY OF TEXAS MD ANDERSON CAN CTR · PI VADLAMUDI, RATNA K · 2003 to 2013
$2.5M
NCI NIH HHS CA095681NCI NIH HHS R01 CA095681NINDS NIH HHS R01 NS050730
6 · The paper itself

Abstract

PELP1 (proline-rich, glutamic acid-rich, and leucine-rich protein-1) is a potential proto-oncogene that functions as a coregulator of estrogen receptor (ER), and its expression is deregulated during breast cancer progression. Emerging evidence suggests growth factor signaling crosstalk with ER as one possible mechanism by which breast tumors acquire resistance to therapy. In this study, we examined mechanisms by which growth factors modulate PELP1 functions, leading to activation of ER. Using in vivo labeling assays, we have found that growth factors promote phosphorylation of PELP1. Utilizing a panel of substrate-specific phosphorylated antibodies, we discovered that growth factor stimulation promotes phosphorylation of PELP1 that is recognized by a protein kinase A (PKA) substrate-specific antibody. Accordingly, growth factor-mediated PELP1 phosphorylation was effectively blocked by PKA-specific inhibitor H89. Utilizing purified PKA enzyme and in vitro kinase assays, we obtained evidence of direct PELP1 phosphorylation by PKA. Using deletion and mutational analysis, we identified PELP1 domains that are phosphorylated by PKA. Interestingly, site-directed mutagenesis of the putative PKA site in PELP1 compromised growth factor-induced activation and subnuclear localization of PELP1 and also affected PELP1-mediated transactivation function. Utilizing MCF-7 cells expressing a PELP1 mutant that cannot be phosphorylated by PKA, we provide mechanistic insights by which growth factor signaling regulates ER transactivation in a PELP1-dependent manner. Collectively, these findings suggest that growth factor signals promote phosphorylation of ER coactivator PELP1 via PKA pathway, and such modification may have functional implications in breast tumors with deregulated growth factor signaling.

Indexed as

Gene Expression Regulation, NeoplasticAnimalsCell Line, TumorChlorocebus aethiopsCo-Repressor ProteinsCOS CellsCyclic AMP-Dependent Protein KinasesGene DeletionHumansIntercellular Signaling Peptides and ProteinsIsoquinolinesMutagenesis, Site-DirectedPhosphorylationProto-Oncogene MasReceptors, EstrogenSignal TransductionCo-Repressor ProteinsCyclic AMP-Dependent Protein KinasesIntercellular Signaling Peptides and ProteinsIsoquinolinesMAS1 protein, humanN-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamidePELP1 protein, humanProto-Oncogene MasReceptors, EstrogenSulfonamidesTrans-ActivatorsTranscription Factors

Identifiers

PMID18505929
PMCPMC2782677
OpenAlexW2149611808

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.